Heartflow (NASDAQ:HTFL) Sets New 52-Week High – Should You Buy?

Heartflow, Inc. (NASDAQ:HTFL) reached a new 52-week high during trading on Thursday . The stock traded as high as $39.45 and last traded at $39.31, with a volume of 514402 shares traded. The stock had previously closed at $36.64.

Wall Street Analysts Forecast Growth

Several research analysts have commented on HTFL shares. Canaccord Genuity Group lifted their price objective on shares of Heartflow from $35.00 to $39.00 and gave the stock a “buy” rating in a research note on Monday, September 22nd. Zacks Research upgraded Heartflow to a “hold” rating in a research report on Wednesday, September 3rd. Stifel Nicolaus started coverage on Heartflow in a research report on Tuesday, September 2nd. They set a “buy” rating and a $35.00 target price for the company. Wall Street Zen upgraded Heartflow to a “hold” rating in a research report on Saturday, August 16th. Finally, Morgan Stanley started coverage on Heartflow in a research report on Tuesday, September 2nd. They set an “equal weight” rating and a $35.00 target price for the company. Four research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $36.60.

Heartflow Stock Up 7.3%

The company has a 50-day simple moving average of $33.27.

Heartflow (NASDAQ:HTFL) last released its quarterly earnings data on Friday, September 19th. The company reported ($1.46) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($1.26). The company had revenue of $43.42 million during the quarter, compared to analysts’ expectations of $43.20 million.

Heartflow Company Profile

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.